Aultman Hospital
- Type
- Teaching hospital
- Where
- Canton, OH
- Medicare CCN
- 360084
- Received
- $883,198 in 117 records, 2020 ($33,026 general, $850,172 research)
- Source
- CMS Open Payments search ↗
On this site
- Nonprofit contractor: Aultman Hospital Fuzzy (name and state)
- Federal award recipient: AULTMAN HOSPITAL Fuzzy (name and state)
- Federal award recipient: AULTMAN HOSPITAL, THE Fuzzy (name and state)
- Lobbying client: AULTMAN HOSPITAL Fuzzy (name and state)
- Lobbying client: AULTMAN HOSPITAL Fuzzy (name and state)
- Trademark owner: Aultman Hospital Fuzzy (name and state)
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2020 | General payment | 23 | $33,026 |
| 2020 | Research payment | 94 | $850,172 |
By company
| Company | Records | Amount | Years |
|---|---|---|---|
| GlaxoSmithKline, LLC. | 15 | $289,462 | 2020 |
| Amgen Inc. | 6 | $169,615 | 2020 |
| Novartis Pharmaceuticals Corporation | 2 | $151,461 | 2020 |
| Boston Scientific Corporation | 17 | $71,687 | 2020 |
| Eli Lilly and Company | 2 | $46,768 | 2020 |
| Kowa Research Institute, Inc. | 13 | $37,186 | 2020 |
| American Regent | 6 | $30,938 | 2020 |
| PFIZER INC. | 10 | $22,477 | 2020 |
| AstraZeneca UK Limited | 1 | $20,022 | 2020 |
| CSL Behring | 11 | $14,938 | 2020 |
| AstraZeneca Pharmaceuticals LP | 4 | $14,149 | 2020 |
| GE HEALTHCARE | 1 | $3,023 | 2020 |
| Medtronic Vascular, Inc. | 1 | $2,595 | 2020 |
| Esperion Therapeutics, Inc. | 6 | $2,412 | 2020 |
| Abbott Laboratories | 3 | $2,025 | 2020 |
| Stryker Corporation | 1 | $1,858 | 2020 |
| Aesculap, Inc. | 1 | $949 | 2020 |
| Sterilmed, Inc. | 12 | $653 | 2020 |
| E.R. Squibb & Sons, L.L.C. | 1 | $550 | 2020 |
| Siemens Medical Solutions USA, Inc. | 1 | $287 | 2020 |
| Olympus America Inc. | 1 | $84 | 2020 |
| Masimo Corporation | 1 | $38 | 2020 |
| Zimmer Biomet Holdings, Inc. | 1 | $12 | 2020 |
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 94 | $850,172 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a v | 14 | $23,699 |
| Space rental or facility fees (teaching hospital only) | 2 | $3,500 |
| Gift | 3 | $2,892 |
| Grant | 1 | $2,595 |
| Charitable Contribution | 1 | $287 |
| Education | 1 | $38 |
| Food and Beverage | 1 | $12 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2020-12-31 | Stryker Corporation | $1,858 | Gift | Cash or cash equivalent | NONE Device, NONE | 2020 | |
| 2020-12-31 | AstraZeneca Pharmaceuticals LP | $550 | Research payment | In-kind items and services | Study of 1st Line Therapy Study of MEDI4736 With Tremelimumab Versus SoC in Non Small Cell Lung Cancer NSCLC NEPTUNE | 2020 | |
| 2020-12-31 | Siemens Medical Solutions USA, Inc. | $287 | Charitable Contribution | In-kind items and services | 2020 | ||
| 2020-12-31 | Masimo Corporation | $38 | Education | In-kind items and services | SET and rainbow SET Device, Devices | 2020 | |
| 2020-12-23 | Esperion Therapeutics, Inc. | $202 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2020 |
| 2020-12-23 | Esperion Therapeutics, Inc. | $202 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2020 |
| 2020-12-21 | Boston Scientific Corporation | $400 | Research payment | Cash or cash equivalent | Resonate Device, Tachy | PREEMPT HF | 2020 |
| 2020-12-18 | Sterilmed, Inc. | $34 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2020 | ||
| 2020-12-15 | GlaxoSmithKline, LLC. | $2,763 | Research payment | Cash or cash equivalent | A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERA | 2020 | |
| 2020-12-10 | Aesculap, Inc. | $949 | Gift | Cash or cash equivalent | 2020 | ||
| 2020-12-01 | Kowa Research Institute, Inc. | $1,290 | Research payment | Cash or cash equivalent | Drug | K-877-302 | 2020 |
| 2020-11-24 | Amgen Inc. | $15,322 | Research payment | Cash or cash equivalent | Repatha Biological, Cardiology | FOURIER OLE (Ph 4) | 2020 |
| 2020-11-24 | GlaxoSmithKline, LLC. | $5,673 | Research payment | Cash or cash equivalent | A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERA | 2020 | |
| 2020-11-23 | Amgen Inc. | $16,304 | Research payment | In-kind items and services | Repatha Biological, Cardiology | FOURIER OLE (Ph 4) | 2020 |
| 2020-11-16 | Esperion Therapeutics, Inc. | $202 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2020 |
| 2020-11-16 | Boston Scientific Corporation | $125 | Research payment | Cash or cash equivalent | Resonate Device, Tachy | PREEMPT HF | 2020 |
| 2020-11-12 | Sterilmed, Inc. | $6 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2020 | ||
| 2020-11-03 | Kowa Research Institute, Inc. | $832 | Research payment | Cash or cash equivalent | Drug | K-877-302 | 2020 |
| 2020-11-02 | Esperion Therapeutics, Inc. | $602 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2020 |
| 2020-11-02 | Boston Scientific Corporation | $516 | Research payment | Cash or cash equivalent | CLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCT | ASAP TOO | 2020 |
| 2020-10-22 | Medtronic Vascular, Inc. | $2,595 | Grant | In-kind items and services | IN.PACT AV Device, Drug-Coated Balloons | 2020 | |
| 2020-10-20 | GlaxoSmithKline, LLC. | $4,895 | Research payment | Cash or cash equivalent | A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERA | 2020 | |
| 2020-10-19 | Boston Scientific Corporation | $1,544 | Research payment | Cash or cash equivalent | ACUITY Device, TACHY | NAVIGATE X4 STUDY | 2020 |
| 2020-10-19 | Boston Scientific Corporation | $200 | Research payment | Cash or cash equivalent | ACUITY Device, TACHY | NAVIGATE X4 STUDY | 2020 |
| 2020-10-15 | American Regent | $3,617 | Research payment | Cash or cash equivalent | INJECTAFER Drug, Anemia | Heart_FID | 2020 |
| 2020-10-07 | Sterilmed, Inc. | $38 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2020 | ||
| 2020-10-05 | Boston Scientific Corporation | $56,917 | Research payment | Cash or cash equivalent | Resonate Device, Tachy | PREEMPT HF | 2020 |
| 2020-10-01 | Kowa Research Institute, Inc. | $2,475 | Research payment | Cash or cash equivalent | Drug | K-877-302 | 2020 |
| 2020-09-23 | Esperion Therapeutics, Inc. | $602 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2020 |
| 2020-09-23 | Esperion Therapeutics, Inc. | $602 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2020 |
| 2020-09-21 | Boston Scientific Corporation | $1,080 | Research payment | Cash or cash equivalent | CLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCT | SFA DES PIVOTAL | 2020 |
| 2020-09-15 | GlaxoSmithKline, LLC. | $889 | Research payment | Cash or cash equivalent | A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERA | 2020 | |
| 2020-09-10 | CSL Behring | $764 | Research payment | Cash or cash equivalent | A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a | 2020 | |
| 2020-09-10 | CSL Behring | $50 | Research payment | Cash or cash equivalent | A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a | 2020 | |
| 2020-09-08 | Boston Scientific Corporation | $263 | Research payment | Cash or cash equivalent | CLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCT | ASAP TOO | 2020 |
| 2020-09-03 | Sterilmed, Inc. | $35 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2020 | ||
| 2020-08-26 | PFIZER INC. | $2,280 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2020 | |
| 2020-08-26 | Kowa Research Institute, Inc. | $952 | Research payment | Cash or cash equivalent | Drug | K-877-302 | 2020 |
| 2020-08-26 | PFIZER INC. | $120 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2020 | |
| 2020-08-26 | CSL Behring | $67 | Research payment | In-kind items and services | A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a | 2020 | |
| 2020-08-21 | Amgen Inc. | $925 | Research payment | In-kind items and services | Neulasta Biological, Oncology | Prospective Observational Study of Onpro vs SOC. | 2020 |
| 2020-08-18 | GlaxoSmithKline, LLC. | $5,324 | Research payment | Cash or cash equivalent | A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERA | 2020 | |
| 2020-08-18 | Kowa Research Institute, Inc. | $386 | Research payment | Cash or cash equivalent | Drug | K-877-302 | 2020 |
| 2020-08-17 | Boston Scientific Corporation | $440 | Research payment | Cash or cash equivalent | CLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCT | SFA DES PIVOTAL | 2020 |
| 2020-08-05 | Sterilmed, Inc. | $51 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2020 | ||
| 2020-08-05 | Sterilmed, Inc. | $7 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2020 | ||
| 2020-08-04 | GlaxoSmithKline, LLC. | $47,223 | Research payment | Cash or cash equivalent | A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERA | 2020 | |
| 2020-08-04 | GlaxoSmithKline, LLC. | $2,572 | Research payment | Cash or cash equivalent | A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERA | 2020 | |
| 2020-07-28 | CSL Behring | $1,027 | Research payment | In-kind items and services | A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a | 2020 | |
| 2020-07-27 | Kowa Research Institute, Inc. | $2,641 | Research payment | Cash or cash equivalent | Drug | K-877-302 | 2020 |
| 2020-07-23 | AstraZeneca UK Limited | $20,022 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2020 | ||
| 2020-07-21 | GlaxoSmithKline, LLC. | $5,803 | Research payment | Cash or cash equivalent | A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERA | 2020 | |
| 2020-07-20 | PFIZER INC. | $19 | Research payment | In-kind items and services | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2020 | |
| 2020-07-12 | AstraZeneca Pharmaceuticals LP | $1,500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | IMFINZI Drug, Oncology | 2020 | |
| 2020-07-09 | AstraZeneca Pharmaceuticals LP | $2,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | LYNPARZA Drug, Oncology | 2020 | |
| 2020-07-08 | American Regent | $10,173 | Research payment | Cash or cash equivalent | INJECTAFER Drug, Anemia | Heart_FID | 2020 |
| 2020-07-07 | GlaxoSmithKline, LLC. | $12,865 | Research payment | Cash or cash equivalent | A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERA | 2020 | |
| 2020-07-02 | Abbott Laboratories | $625 | Research payment | Cash or cash equivalent | ABSORB Device, Vascular | ABSORB III Randomized Controlled Trial (RCT) (ABSORB-III) | 2020 |
| 2020-06-24 | Sterilmed, Inc. | $7 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2020 | ||
| 2020-06-18 | Sterilmed, Inc. | $274 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2020 | ||
| 2020-06-18 | Sterilmed, Inc. | $29 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2020 | ||
| 2020-06-17 | PFIZER INC. | $47 | Research payment | In-kind items and services | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2020 | |
| 2020-06-09 | Novartis Pharmaceuticals Corporation | $15,376 | Research payment | Cash or cash equivalent | A RANDOMIZED DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER TRIAL ASSESSING THE IMPACT OF LIPOPROTEIN (A) LOWERING WITH T | 2020 | |
| 2020-06-04 | CSL Behring | $837 | Research payment | Cash or cash equivalent | A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a | 2020 | |
| 2020-05-27 | PFIZER INC. | $12,540 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2020 | |
| 2020-05-27 | GlaxoSmithKline, LLC. | $5,914 | Research payment | Cash or cash equivalent | A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERA | 2020 | |
| 2020-05-27 | PFIZER INC. | $3,200 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2020 | |
| 2020-05-27 | PFIZER INC. | $1,846 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2020 | |
| 2020-05-27 | PFIZER INC. | $1,600 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2020 | |
| 2020-05-27 | PFIZER INC. | $601 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2020 | |
| 2020-05-26 | Kowa Research Institute, Inc. | $2,092 | Research payment | Cash or cash equivalent | Drug | K-877-302 | 2020 |
| 2020-05-18 | Boston Scientific Corporation | $599 | Research payment | Cash or cash equivalent | CLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCT | SFA DES PIVOTAL | 2020 |
| 2020-05-14 | CSL Behring | $706 | Research payment | Cash or cash equivalent | A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a | 2020 | |
| 2020-05-12 | Kowa Research Institute, Inc. | $223 | Research payment | Cash or cash equivalent | Drug | K-877-302 | 2020 |
| 2020-05-11 | American Regent | $170 | Research payment | Cash or cash equivalent | INJECTAFER Drug, Anemia | Heart_FID | 2020 |
| 2020-05-06 | Kowa Research Institute, Inc. | $376 | Research payment | Cash or cash equivalent | Drug | K-877-302 | 2020 |
| 2020-05-04 | Boston Scientific Corporation | $1,658 | Research payment | Cash or cash equivalent | ACUITY Device, TACHY | NAVIGATE X4 STUDY | 2020 |
| 2020-05-04 | Boston Scientific Corporation | $200 | Research payment | Cash or cash equivalent | ACUITY Device, TACHY | NAVIGATE X4 STUDY | 2020 |
| 2020-04-28 | GlaxoSmithKline, LLC. | $20,893 | Research payment | Cash or cash equivalent | A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERA | 2020 | |
| 2020-04-27 | Kowa Research Institute, Inc. | $448 | Research payment | Cash or cash equivalent | Drug | K-877-302 | 2020 |
| 2020-04-27 | CSL Behring | $82 | Research payment | In-kind items and services | A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a | 2020 | |
| 2020-04-20 | Boston Scientific Corporation | $440 | Research payment | Cash or cash equivalent | CLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCT | SFA DES PIVOTAL | 2020 |
| 2020-04-14 | CSL Behring | $250 | Research payment | Cash or cash equivalent | A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a | 2020 | |
| 2020-04-09 | CSL Behring | $5,142 | Research payment | Cash or cash equivalent | A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a | 2020 | |
| 2020-04-08 | American Regent | $4,642 | Research payment | Cash or cash equivalent | INJECTAFER Drug, Anemia | Heart_FID | 2020 |
| 2020-04-06 | GlaxoSmithKline, LLC. | $10,969 | Research payment | Cash or cash equivalent | A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERA | 2020 | |
| 2020-03-25 | Sterilmed, Inc. | $63 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2020 | ||
| 2020-03-24 | GlaxoSmithKline, LLC. | $73,515 | Research payment | Cash or cash equivalent | A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERA | 2020 | |
| 2020-03-18 | Kowa Research Institute, Inc. | $8,576 | Research payment | Cash or cash equivalent | Drug | K-877-302 | 2020 |
| 2020-03-18 | Olympus America Inc. | $84 | Gift | In-kind items and services | Olympus GI Accessories Device, EndoTherapy Products | 2020 | |
| 2020-03-16 | GlaxoSmithKline, LLC. | $6,258 | Research payment | Cash or cash equivalent | A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERA | 2020 | |
| 2020-03-12 | CSL Behring | $5,810 | Research payment | Cash or cash equivalent | A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a | 2020 | |
| 2020-03-12 | Abbott Laboratories | $700 | Research payment | Cash or cash equivalent | ABSORB Device, Vascular | ABSORB III Randomized Controlled Trial (RCT) (ABSORB-III) | 2020 |
| 2020-03-12 | CSL Behring | $200 | Research payment | Cash or cash equivalent | A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a | 2020 | |
| 2020-03-09 | American Regent | $500 | Research payment | Cash or cash equivalent | INJECTAFER Drug, Anemia | Heart_FID | 2020 |
| 2020-03-04 | GE HEALTHCARE | $3,023 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2020 | ||
| 2020-03-02 | Boston Scientific Corporation | $6,024 | Research payment | Cash or cash equivalent | CLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCT | ASAP TOO | 2020 |
| 2020-03-02 | Zimmer Biomet Holdings, Inc. | $12 | Food and Beverage | In-kind items and services | SternaLock Blu Device, CMF & Thoracic | 2020 | |
| 2020-02-24 | GlaxoSmithKline, LLC. | $83,901 | Research payment | Cash or cash equivalent | A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERA | 2020 | |
| 2020-02-21 | Kowa Research Institute, Inc. | $6,565 | Research payment | Cash or cash equivalent | Drug | K-877-302 | 2020 |
| 2020-02-18 | Boston Scientific Corporation | $635 | Research payment | Cash or cash equivalent | ACUITY Device, TACHY | NAVIGATE X4 STUDY | 2020 |
| 2020-02-18 | Boston Scientific Corporation | $440 | Research payment | Cash or cash equivalent | CLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCT | SFA DES PIVOTAL | 2020 |
| 2020-02-05 | Sterilmed, Inc. | $91 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2020 | ||
| 2020-01-31 | Amgen Inc. | $23,585 | Research payment | Cash or cash equivalent | Repatha Biological, Cardiology | FOURIER OLE (Ph 4) | 2020 |
| 2020-01-30 | Amgen Inc. | $12,350 | Research payment | Cash or cash equivalent | Neulasta Biological, Oncology | Prospective Observational Study of Onpro vs SOC. | 2020 |
| 2020-01-28 | E.R. Squibb & Sons, L.L.C. | $550 | Research payment | Cash or cash equivalent | OPDIVO Biological, Oncology | A US Multi-Site Observational Study in Patients With Unresectable And Metastatic Melanoma: The OPTIMIzE Study | 2020 |
| 2020-01-28 | Eli Lilly and Company | $358 | Research payment | In-kind items and services | A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF ABEMACICLIB COMBINED WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD | 2020 | |
| 2020-01-27 | Novartis Pharmaceuticals Corporation | $136,084 | Research payment | Cash or cash equivalent | ENTRESTO Drug, CARDIOVASCULAR | PROSPECTIVE COMPARISON OF ANGIOTENSIN RECEPTOR NEPRILYSIN INHIBITOR ARNI VERSUS ACE INHIBITOR TRIAL TO DETERMINE IMPACT | 2020 |
| 2020-01-21 | Kowa Research Institute, Inc. | $10,325 | Research payment | Cash or cash equivalent | Drug | K-877-302 | 2020 |
| 2020-01-21 | Boston Scientific Corporation | $200 | Research payment | Cash or cash equivalent | CLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCT | SFA DES PIVOTAL | 2020 |
| 2020-01-17 | Sterilmed, Inc. | $13 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2020 | ||
| 2020-01-16 | AstraZeneca Pharmaceuticals LP | $10,098 | Research payment | Cash or cash equivalent | Study of 1st Line Therapy Study of MEDI4736 With Tremelimumab Versus SoC in Non Small Cell Lung Cancer NSCLC NEPTUNE | 2020 | |
| 2020-01-16 | PFIZER INC. | $221 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2020 | |
| 2020-01-13 | American Regent | $11,836 | Research payment | Cash or cash equivalent | INJECTAFER Drug, Anemia | Heart_FID | 2020 |
| 2020-01-13 | Abbott Laboratories | $700 | Research payment | Cash or cash equivalent | ABSORB Device, Vascular | ABSORB III Randomized Controlled Trial (RCT) (ABSORB-III) | 2020 |
| 2020-01-10 | Amgen Inc. | $101,128 | Research payment | In-kind items and services | Repatha Biological, Cardiology | FOURIER OLE (Ph 4) | 2020 |
| 2020-01-07 | Eli Lilly and Company | $46,410 | Research payment | Cash or cash equivalent | A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF ABEMACICLIB COMBINED WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD | 2020 |
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Canton, OH, county Stark County, OH, state Ohio; placed by its city name.
| Measure | Place (city or town) Canton, OH | County Stark County, OH | State Ohio |
|---|---|---|---|
| Population B01003 | 69,755 | 373,713 | 11,810,293 |
| Population, 2020 census P1 | 70,872 | 374,853 | 11,799,448 |
| Median age B01002 | 35.2 | 41.8 | 39.7 |
| Under 18 B01001 | 25.4% | 21.5% | 22.0% |
| 65 and over B01001 | 15.7% | 20.5% | 18.3% |
| Households B11001 | 29,302 | 155,955 | 4,863,191 |
| Foreign born B05002 | 2.5% | 2.2% | 5.2% |
| Median household income B19013 | $43,188 | $67,934 | $71,389 |
| Median family income B19113 | $53,992 | $86,156 | $92,749 |
| Per capita income B19301 | $24,690 | $36,762 | $40,552 |
| Poverty rate B17001 | 27.4% | 12.5% | 13.3% |
| Unemployment rate B23025 | 7.8% | 3.9% | 4.8% |
| Civilian labor force B23025 | 32,390 | 186,713 | 5,994,779 |
| Mean commute (minutes) B08013 | 19.1 | 21.7 | 23.4 |
| Bachelor's degree or higher B15003 | 16.4% | 25.9% | 31.5% |
| Housing units B25001 | 33,836 | 167,949 | 5,292,391 |
| Owner-occupied B25003 | 48.7% | 69.2% | 67.2% |
| Renters B25003 | 51.3% | 30.8% | 32.8% |
| Median home value B25077 | $97,800 | $186,400 | $214,800 |
| Median gross rent B25064 | $850 | $909 | $1,034 |
| White, not Hispanic B03002 | 59.0% | 83.8% | 75.8% |
| Black B03002 | 23.4% | 7.1% | 12.0% |
| Hispanic or Latino B03002 | 6.7% | 3.0% | 4.8% |
| Asian B03002 | 0.6% | 0.9% | 2.5% |
| American Indian and Alaska Native B03002 | 0.0% | 0.1% | 0.1% |
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Canton, OH.
Comments